Mary T. Korytkowski, MD, MSN Professor of Medicine Division of Endocrinology & Metabolism University of Pittsburgh Pittsburgh, PA
AMA PRA Category 1 Credit TM Medium
Primary care practitioners (PCPs) play an important role in helping patients with type 2 diabetes mellitus (T2DM) achieve better glucose control, and encouraging PCPs to become “early adopters” of insulin therapy could result in patients experiencing less chronic hyperglycemia. Insulin therapy initiation can require greater use of resources, time, and effort on the part of both the clinician and the patient, and patient resistance to insulin therapy is common. Critical to all of this are the discussions between health care clinicians and patients regarding the importance of glycemic control, their role in monitoring and managing their diabetes, the importance of intensifying treatment regimens, and the importance of managing complications associated with the therapy.
The goal of this continuing education activity is to expand competency and build skills among PCPs to overcome barriers to more effective glycemic control in their patients with T2DM by improving communications with their patients and, ultimately, improving patient outcomes.
. Target Audience
Family physicians, internists, and general practitioners, as well as other physicians, nurse practitioners, physician assistants and nurses who practice in the primary care setting.
Upon completion of this educational activity, the participant should be able to:
Presentation: Outline strategies to overcome barriers to initiation of insulin therapy in adults with T2DM.
Presentation: Utilize effective glucose monitoring strategies and current technologies to minimize complications, eg, hypoglycemia.
Patient Simulations: Enhance patient communication skills to improve patients' understanding and abilities to manage their T2DM.
Patient Simulations: Develop effective insulin intensification strategies to improve glycemic control in patients with T2DM.
Patient Simulations: Consider comorbidities and complications of T2DM when developing individualized treatment.
The University of Cincinnati is committed to offering CME programs that promote improvements or quality in healthcare. It is our policy to ensure balance, independence, objectivity, and scientific rigor in all of our sponsored educational programs. Faculty are required to disclose any real or apparent conflict(s) of interest related to the content of this CME activity. Disclosure of a relationship is not intended to suggest or condone bias, but is made to provide learners with information that may be of importance in their evaluation of the materials.
Dr. Korytkowski discloses that she receives research funding from Sanofi-Aventis and is a consultant to Regeneron.
Planning Committee Disclosure Statement
These additional planning committee members have no financial relationships to disclose: Sara Thier, PhD, MPH; Jennifer Lukondi; Susan P. Tyler, M.Ed, CMP, CCMEP; and Rick Ricer, MD.
Product Disclosure Information
Faculty members are required to inform the audience when they are discussing off-label or unapproved uses of devices or drugs. Devices or drugs that are still undergoing clinical trials are identified as such and should not be portrayed as standard, accepted therapy. Please consult the full prescribing information before using any product mentioned in the activity. When using drugs in an investigational, off-label manner, it is the responsibility of the prescribing physician to monitor the medical literature to determine recommended dosage and uses of the drugs. Neither the publisher nor the sponsor promotes the use of any agent outside of approved labeling. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity has been planned and implemented in accordance with the Essentials Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Cincinnati and MCM Education. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
University of Cincinnati designates this Enduring Material for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
University of Cincinnati
Continuing Medical Education
3225 Eden Avenue, G24 Wherry Hall
Cincinnati, OH 45267
Commercial Support Statements
This activity is supported by an independent educational grant from Eli Lilly and Company.
Minimum System Requirements:
• 1 GHz or Equivalent Processor
• 1 GB of RAM • Windows XP, Vista, 7, or 8
• Mac OS X • iOS 5 or 6
• 1024x768 Monitor Resolution
• Browsers: IE9+, Chrome 25+, Firefox 19+, Safari 5+
• 16-bit Color
• 16 bit Sound Card with Speakers/Headphones
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 60 minutes to complete.
After the activity has finished, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.
©2013, MCM Education. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, University of Cincinnati Office of CME, or Eli Lilly and Company. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.